Atomoxetine for the Treatment of Pediatric Nocturnal Enuresis

Shatkin, Jess P.

doi:10.1089/cap.2004.14.443

Cited by 22 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serotonin and/or noradrenaline reuptake inhibitors (SNRIs) such as atomoxetine are used in the treatment of ADHD as well as anxiety/depression and autism, and there have been some anti-enuretic effects noted in studies [ 28 ]. In children with nocturnal enuresis and ADHD, the use of atomoxetine in combination with other medications was effective in a 4-child case series [ 30 ].…”

Section: Resultsmentioning

confidence: 99%

Optimising the management of children with concomitant bladder dysfunction and behavioural disorders

Eliezer

Lam

Smith

et al. 2022

Eur Child Adolesc Psychiatry

View full text Add to dashboard Cite

Bladder dysfunction and behavioural disorders in children are commonly concomitant; hence, it is difficult to treat each in isolation. Pharmacotherapy is common treatment for behavioural disorders, and these medications may have intended or unintended positive or negative bladder sequelae. This review identifies the literature regarding the effects of behavioural pharmacotherapy on bladder functioning and possible bladder management strategies in children with concomitant behaviour and bladder disorders to enable clinicians to better manage both conditions. A PROSPERO registered PRISMA-guided review of three major databases was performed. After an initial scoping study revealed significant heterogeneity, a narrative approach was undertaken to discuss the results of all relevant cases relating to children being treated with pharmacotherapy for behaviour disorders and outcomes related to bladder function. Studies were screened to identify those that described effects of commonly prescribed medications in children with behavioural disorders such as stimulants, alpha 2 agonists, tricyclic antidepressants (TCA), serotonin and noradrenergic reuptake inhibitors (SNRI), selective serotonin reuptake inhibitors (SSRI) and antipsychotics, and the findings and implications were summarised. The review identified 46 studies relevant to behavioural pharmacotherapy and bladder function (stimulants (n = 9), alpha 2 agonists (n = 2), TCAs (n = 7), SNRIs (n = 8), SSRIs (n = 8) and antipsychotics (n = 6). Six studies focused specifically on bladder management in children with behavioural disorders with concurrent behavioural pharmacotherapy. This review identifies useful factors that may assist clinicians with predicting unintended bladder effects following initiation of behavioural pharmacotherapy to facilitate the best approach to the treatment of bladder dysfunction in children with behavioural disorders. With this evidence, we have provided a useful decision-making algorithm to aide clinicians in the management of these dual pathologies.

show abstract

Section: Resultsmentioning

confidence: 99%

Optimising the management of children with concomitant bladder dysfunction and behavioural disorders

Eliezer

Lam

Smith

et al. 2022

Eur Child Adolesc Psychiatry

View full text Add to dashboard Cite

show abstract

“…3 There are reports that the use of atomoxetine in the presence of depression, anxiety, tic disorder, or nocturnal enuresis coexisting with ADHD has possible advantages. [8][9][10] The use of atomoxetine is known to cause side effects such as headache, sleep disorders, increases in blood pressure, cardiac problems, suicidal tendencies, and restlessness. 8,11 However, in the literature, only 1 case report has indicated that atomoxetine causes OCD.…”

Section: Discussionmentioning

confidence: 99%

Atomoxetine Induced Obsessive-Compulsive Disorder

Altay

2019

Hosp Pract Res

View full text Add to dashboard Cite

Introduction: Attention deficit and hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in children and adolescents. Atomoxetine is a non-stimulant drug used in the treatment of ADHD. Case Presentation: In this article, a case of obsessive-compulsive disorder (OCD) which occurred in an 11-year-old boy with an increased dose of atomoxetine during ADHD treatment and disappeared with dose reduction is reported. This case is only the second OCD case resulting from the use of atomoxetine. Conclusion: The case reported herein is the second case caused by the use of atomoxetine and the first in which OCD symptoms regressed when the atomoxetine dose was reduced. OCD development due to atomoxetine consumption may occur at different doses. When OCD develops, the solution may be dose reduction, or it may be necessary to discontinue treatment with atomoxetine.

show abstract